Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-α-2b in patients with advanced gastric carcinoma

European Journal of Cancer Part A

Volumn 32, Issue 7, 1996, Pages 1254-1256

  Wadler, S ^a   Gleissner, B ^a   Hilgenfeld, R U ^a   Thiel, E ^a   Haynes, H ^a   Kaleya, R ^a   Rozenblit, A ^a   Kreuser, E D ^a  

^a NONE

Author keywords

5 fluorouracil; biochemical modulation; gastric cancer; interferon a 2b; N (phosphonacetyl) L aspartate (PALA)

Indexed keywords

FLUOROURACIL; RECOMBINANT ALPHA2B INTERFERON; SPARFOSIC ACID;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; FATIGUE; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CARCINOMA; STOMATITIS; THROMBOCYTOPENIA;

EID: 0030176137     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00035-4     Document Type: Article

References (15)

1. 1. Wadler S, Green MD, Muggia FM. The role of anthracyclines in the treatment of gastric cancer. Cancer Treat Rev 1985, 12, 105-132.
2. 2. Preusser P, Wilke H, Achterrath W, et al. Phase II study with the combination, etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989, 7, 1310-1317.
3. 3. Sparano JA, Schwartz EL, Salva KM, Pizzillo MF, Wadler S, Wiernik PH. Phase II trial of etoposide (VP16), doxorubicin (Adriamycin) and cisplatin (EAP) in advanced gastric cancer. Am J Clin Oncol 1990, 13, 374-378.
4. 4. Taal BG, Teller FGM, ten Bokkel Huinink WW, Boot H, Beijnen JH, Dubbelman R. Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide. Ann Oncol 1994, 5, 90-92.
5. 5. Kelsen D, Atiq OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992, 10, 541-548.
6. 6. Grem JL, King SA, O'Dwyer PJ, Leyland-Jones B. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review. Cancer Res 1988, 48, 4441-4454.
7. 7. Windschitl HE, O'Connell MJ, Wieand HS, et al. A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer. Cancer 1990, 66, 853-856.
8. 8. Wadler S, Schwartz EL. New clinical directions for the combination of 5-fluorouracil and interferon. J Infusional Chemother 1993, 3, 160-164.
9. 9. Simon RM. Design and conduct of clinical trials. In DeVita VT, Hellman S, Rosenberg S, eds. Cancer: Principles and Practice of Oncology, 3rd edn. New York, JB Lippincott, 1989, 396-420.
10. 10. National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda, Maryland, Division of Cancer Treatment, National Cancer Institute, 1988.
11. 11. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5, 649-655.
12. 12. Moore EC, Friedman J, Valdivieso M, et al. Aspartate carbamoyl-transferase activity, drug concentrations and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate. Biochem Pharmacol 1982, 31, 3317-3321.
13. 13. Ardalan B, Glazer RI, Kensler TW, et al. Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-aspartate on cell growth and ribonucleic acid synthesis in a human mammary carcinoma. Biochem Pharmacol 1981, 30, 2045-2049.
14. 14. Liang C-M, Donehower RC, Chabner BC. Biochemical interactions between N-(phosphonacetyl)-L-aspartate and 5-fluorouracil. Molec Pharmacol 1982, 21, 224-230.
15. 15. Wadler S, Mao X, Bajaj R, Schwartz EL. Interaction between 5-fluorouracil/interferon-α-2a and N-(phosphonacetyl)-L-aspartate (PALA) in human colon cancer cell lines is mediated through RNA effects. Molec Pharmacol 1993, 44, 1070-1076.